Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 3
2007 2
2008 2
2009 1
2011 1
2012 2
2013 4
2014 3
2015 6
2016 7
2017 6
2018 5
2019 3
2020 6
2021 3
2022 6
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Results by year

Filters applied: . Clear all
Page 1
Identification of Differential Tumor Subtypes of T1 Bladder Cancer.
Robertson AG, Groeneveld CS, Jordan B, Lin X, McLaughlin KA, Das A, Fall LA, Fantini D, Taxter TJ, Mogil LS, Lindskrog SV, Dyrskjøt L, McConkey DJ, Svatek RS, de Reyniès A, Castro MAA, Meeks JJ. Robertson AG, et al. Eur Urol. 2020 Oct;78(4):533-537. doi: 10.1016/j.eururo.2020.06.048. Epub 2020 Jul 17. Eur Urol. 2020. PMID: 32684305
The T1-LumGU subtype was associated with carcinoma in situ (CIS; six/13, 46% of all CIS), had high E2F1 and EZH2 expression, and was enriched in E2F target and G2M checkpoint hallmarks. ...
The T1-LumGU subtype was associated with carcinoma in situ (CIS; six/13, 46% of all CIS), had high E2F1 and EZH2 expression, and was …
ARID1A-deficient bladder cancer is dependent on PI3K signaling and sensitive to EZH2 and PI3K inhibitors.
Rehman H, Chandrashekar DS, Balabhadrapatruni C, Nepal S, Balasubramanya SAH, Shelton AK, Skinner KR, Ma AH, Rao T, Agarwal S, Eich ML, Robinson AD, Naik G, Manne U, Netto GJ, Miller CR, Pan CX, Sonpavde G, Varambally S, Ferguson JE 3rd. Rehman H, et al. JCI Insight. 2022 Aug 22;7(16):e155899. doi: 10.1172/jci.insight.155899. JCI Insight. 2022. PMID: 35852858 Free PMC article.
Chromatin modifiers are frequently mutated in bladder cancer, with ARID1A-inactivating mutations present in about 20% of tumors. EZH2, a histone methyltransferase, acts as an oncogene that functionally opposes ARID1A. ...Furthermore, ARID1A-deficient bladder cancer was sen …
Chromatin modifiers are frequently mutated in bladder cancer, with ARID1A-inactivating mutations present in about 20% of tumors. EZH2 …
EZH2 in Bladder Cancer, a Promising Therapeutic Target.
Martínez-Fernández M, Rubio C, Segovia C, López-Calderón FF, Dueñas M, Paramio JM. Martínez-Fernández M, et al. Int J Mol Sci. 2015 Nov 13;16(11):27107-32. doi: 10.3390/ijms161126000. Int J Mol Sci. 2015. PMID: 26580594 Free PMC article. Review.
EZH2 is frequently overexpressed in multiple tumor types, including BC, and plays multiple roles besides the well-recognized histone mark generation. In this review, we summarize the present knowledge on the oncogenic roles of EZH2 and its potential use as a therape …
EZH2 is frequently overexpressed in multiple tumor types, including BC, and plays multiple roles besides the well-recognized histone …
Inhibition of EZH2 induces NK cell-mediated differentiation and death in muscle-invasive bladder cancer.
Ramakrishnan S, Granger V, Rak M, Hu Q, Attwood K, Aquila L, Krishnan N, Osiecki R, Azabdaftari G, Guru K, Chatta G, Gueron G, McNally L, Ohm J, Wang J, Woloszynska A. Ramakrishnan S, et al. Cell Death Differ. 2019 Oct;26(10):2100-2114. doi: 10.1038/s41418-019-0278-9. Epub 2019 Jan 28. Cell Death Differ. 2019. PMID: 30692641 Free PMC article.
We reveal a novel mechanism of action of EZH2 inhibition, alone and in combination with cisplatin, which induces immune signaling with the largest changes observed in interferon gamma (IFN-gamma). This upregulation is a result of activated natural killer (NK) signaling as …
We reveal a novel mechanism of action of EZH2 inhibition, alone and in combination with cisplatin, which induces immune signaling wit …
Prognostic significance of EZH2 and ARID1A expression in urothelial carcinoma: an immunohistochemical study.
Sameh R, Mostafa N, Ramadan M, AbdelRaouf S, Abdelwahab K. Sameh R, et al. J Histotechnol. 2022 Mar;45(1):21-28. doi: 10.1080/01478885.2021.1973309. Epub 2021 Sep 8. J Histotechnol. 2022. PMID: 34493171
Enhancer of zeste homolog 2 (EZH2) and AT-rich interactive domain 1A (ARID1A) expression in urothelial carcinoma (UC) has not been well studied. ...Amplification of EZH2 has been reported in several malignancies. This study analyzed the immunohistochemical expressio …
Enhancer of zeste homolog 2 (EZH2) and AT-rich interactive domain 1A (ARID1A) expression in urothelial carcinoma (UC) has not been we …
Retinoids and EZH2 inhibitors cooperate to orchestrate anti-oncogenic effects on bladder cancer cells.
Ozgun G, Yaras T, Akman B, Özden-Yılmaz G, Landman N, Karakülah G, van Lohuizen M, Senturk S, Erkek-Ozhan S. Ozgun G, et al. Cancer Gene Ther. 2024 Apr;31(4):537-551. doi: 10.1038/s41417-024-00725-3. Epub 2024 Jan 17. Cancer Gene Ther. 2024. PMID: 38233533
Therefore, our aim is to simultaneously target EZH2 and retinoic acid signaling in bladder cancer to potentiate the therapeutic response. ...These findings highlight the importance of co-targeting the EZH2 and retinoic acid pathway in bladder cancers and encourage t …
Therefore, our aim is to simultaneously target EZH2 and retinoic acid signaling in bladder cancer to potentiate the therapeutic respo …
Nested quantitative PCR approach for urinary cell-free EZH2 mRNA and its potential clinical application in bladder cancer.
Zhang X, Zhang Y, Liu X, Liu T, Li P, Du L, Yang Y, Wang L, Wang C. Zhang X, et al. Int J Cancer. 2016 Oct 15;139(8):1830-8. doi: 10.1002/ijc.30230. Epub 2016 Jun 28. Int J Cancer. 2016. PMID: 27300769 Free article.
EZH2 is overexpressed in bladder cancer (BC) and plays important roles in tumor development and progression. ...Compared with cytology, cf-EZH2 mRNA showed higher diagnostic ability for MIBC (p < 0.001) while not for NMIBC (p > 0.05). ...
EZH2 is overexpressed in bladder cancer (BC) and plays important roles in tumor development and progression. ...Compared with cytolog …
Expression of EZH2 and H3K27me3 predicts tumor biology of urothelial carcinoma.
Mohamedali R, Mitra S, Mandal S, Nayak P, Adhya AK, Purkait S. Mohamedali R, et al. Indian J Pathol Microbiol. 2023 Jul-Sep;66(3):488-494. doi: 10.4103/ijpm.ijpm_1267_21. Indian J Pathol Microbiol. 2023. PMID: 37530328 Free article.
AIM: To assess the role of EZH2 and H3K27me3 in the carcinogenesis of urothelial carcinoma of urinary bladder. ...RESULTS: EZH2 showed a significant correlation with the tumor grade and lamina propria invasion (p < 0.001). ...
AIM: To assess the role of EZH2 and H3K27me3 in the carcinogenesis of urothelial carcinoma of urinary bladder. ...RESULTS: EZH2 …
Long non-coding RNA SNHG1 promotes bladder cancer progression by upregulating EZH2 and repressing KLF2 transcription.
Min J, Ma J, Wang Q, Yu D. Min J, et al. Clinics (Sao Paulo). 2022 Sep 7;77:100081. doi: 10.1016/j.clinsp.2022.100081. eCollection 2022. Clinics (Sao Paulo). 2022. PMID: 36087568 Free PMC article.
METHOD: The expression, prognostic value, diagnostic value, and correlation of SNHG1, Enhancer of Zeste 2 polycomb repressive complex 2 subunit (EZH2), and Kruppel Like Factor 2 (KLF2) were analyzed through bioinformatics analysis. ...In the cytoplasm, SNHG1 acted as a com …
METHOD: The expression, prognostic value, diagnostic value, and correlation of SNHG1, Enhancer of Zeste 2 polycomb repressive complex 2 subu …
Pre-clinical investigation of STAT3 pathway in bladder cancer: Paving the way for clinical translation.
Mirzaei S, Gholami MH, Mahabady MK, Nabavi N, Zabolian A, Banihashemi SM, Haddadi A, Entezari M, Hushmandi K, Makvandi P, Samarghandian S, Zarrabi A, Ashrafizadeh M, Khan H. Mirzaei S, et al. Biomed Pharmacother. 2021 Jan;133:111077. doi: 10.1016/j.biopha.2020.111077. Epub 2020 Dec 4. Biomed Pharmacother. 2021. PMID: 33378975 Free article. Review.
BC cells obtain chemoresistance via STAT3 overexpression and its inhibition paves the way for increasing efficacy of chemotherapy. Different molecular pathways such as KMT1A, EZH2, DAB2IP and non-coding RNAs including microRNAs and long non-coding RNAs can function as upst …
BC cells obtain chemoresistance via STAT3 overexpression and its inhibition paves the way for increasing efficacy of chemotherapy. Different …
53 results